Related Experiment Videos
Cardiomyopathy induced by anthracycline-derivates
Acta Paediatrica Scandinavica
|May 1, 1984
Summary
Regular cardiac monitoring during anthracycline therapy can detect early signs of heart failure. Left ventricular systolic time intervals (LSTI) indicate cardiotoxicity before echocardiography, guiding treatment decisions.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Anthracyclines are potent chemotherapy agents with known cardiotoxic potential.
- Congestive heart failure is a serious adverse effect of anthracycline treatment.
- Early detection of cardiotoxicity is crucial for patient management.
Observation:
- This study describes two cases of anthracycline-induced congestive heart failure.
- Serial cardiac function assessments were performed during anthracycline therapy.
- Early deterioration of left ventricular systolic time intervals (LSTI) was observed.
Findings:
- Left ventricular systolic time intervals (LSTI) showed early signs of cardiac dysfunction.
- Echocardiography detected congestive cardiomyopathy later than LSTI changes.
- A significant LSTI increase (over 50%) or a value of 0.45 suggests stopping anthracycline therapy.
Implications:
- Regular monitoring of cardiac function using LSTI and echocardiography is recommended during anthracycline treatment.
- Prompt intervention based on LSTI values can prevent severe cardiotoxicity.
- This approach aids in optimizing cancer treatment while minimizing cardiac risks.